Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) — Working Capital to Net Assets Ratio
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has a Working Capital to Net Assets ratio of 78.3% as of March 2026. Working capital of CN¥4.44 Billion (current assets of CN¥4.70 Billion minus current liabilities of CN¥256.07 Million) is measured against net assets of CN¥5.67 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. For the complete balance sheet picture, see 002932 current and non-current assets.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Working Capital to Net Assets (2011–2025)
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 78.3%, reflecting working capital of CN¥4.44 Billion against net assets of CN¥5.67 Billion CNY. Explore 002932 capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Annual Working Capital to Net Assets for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read 002932 liabilities breakdown for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 78.5% | CN¥4.44 Billion | CN¥5.66 Billion | CN¥4.68 Billion | CN¥240.99 Million | ▲ +46.9 pp |
| 2024 | 31.6% | CN¥1.90 Billion | CN¥6.02 Billion | CN¥2.40 Billion | CN¥495.86 Million | ▲ +4.1 pp |
| 2023 | 27.5% | CN¥1.73 Billion | CN¥6.29 Billion | CN¥2.75 Billion | CN¥1.02 Billion | ▼ -51.0 pp |
| 2022 | 78.5% | CN¥5.32 Billion | CN¥6.77 Billion | CN¥7.68 Billion | CN¥2.36 Billion | ▼ -7.6 pp |
| 2021 | 86.1% | CN¥2.45 Billion | CN¥2.85 Billion | CN¥3.00 Billion | CN¥545.98 Million | ▲ +4.6 pp |
| 2020 | 81.5% | CN¥908.68 Million | CN¥1.11 Billion | CN¥1.22 Billion | CN¥309.42 Million | ▲ +8.2 pp |
| 2019 | 73.4% | CN¥451.59 Million | CN¥615.62 Million | CN¥471.90 Million | CN¥20.32 Million | ▼ -8.3 pp |
| 2018 | 81.7% | CN¥483.95 Million | CN¥592.59 Million | CN¥505.61 Million | CN¥21.67 Million | ▲ +17.8 pp |
| 2017 | 63.8% | CN¥155.05 Million | CN¥242.93 Million | CN¥167.22 Million | CN¥12.17 Million | ▼ -7.2 pp |
| 2016 | 71.0% | CN¥124.33 Million | CN¥175.08 Million | CN¥145.29 Million | CN¥20.95 Million | ▼ -15.4 pp |
| 2015 | 86.4% | CN¥99.72 Million | CN¥115.39 Million | CN¥117.67 Million | CN¥17.95 Million | ▲ +12.9 pp |
| 2014 | 73.6% | CN¥36.47 Million | CN¥49.59 Million | CN¥47.79 Million | CN¥11.31 Million | ▲ +47.9 pp |
| 2013 | 25.6% | CN¥3.49 Million | CN¥13.60 Million | CN¥13.55 Million | CN¥10.06 Million | ▲ +3.5 pp |
| 2012 | 22.1% | CN¥314.72K | CN¥1.42 Million | CN¥3.31 Million | CN¥3.00 Million | ▲ +380.5 pp |
| 2011 | -358.4% | CN¥-76.88K | CN¥21.45K | CN¥1.51 Million | CN¥1.59 Million | — |